gip and glp 1 drugs The dual glucose-dependent insulinotropic polypeptide (GIP) glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect | Cardiovascular Diabetology Frontiers | Clinical perspectives on
Description
Saxenda is administered once a day by subcutaneous injection
Others have moved in the opposite direction, limiting coverage due to budget concerns
Lepore JJ, Olson E, Demopoulos L, et al
:max_bytes(150000):strip_icc()/health-GettyImages-2025836701-ce3f5ccf0f98428e9d14abaeb07ba307.jpg)
This article breaks down the science, clinical trial results, and real-world experiences with these medications to help you understand their role in weight loss
